Adlai Nortye Group (ANL) vs Janux Therapeutics (JANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Janux Therapeutics (JANX) over the past year, gaining 796.5% versus a loss of 23.6%. Janux Therapeutics is the larger company by market cap ($1.13 billion vs $998.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | JANX |
|---|---|---|
| Share price | $15.51 | $18.50 |
| Market cap | $998.81M | $1.13B |
| 1-day change | +10.39% | +3.24% |
| YTD return | +992.25% | +34.06% |
| 1-year return | +796.53% | -23.55% |
| 5-year return | — | -15.19% |
| EPS (TTM) | $-0.66 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $35.34 |
| 52-week low | $0.879 | $12.12 |
| Distance from 52-week high | -10.09% | -47.65% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +90.20% | +95.89% |
| Average volume | 175.26K | 845.95K |
| Shares outstanding | 58.73M | 61.14M |
| Employees | 109 | 113 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed JANX by 820.1 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Healthcare · Biotechnology · 109 employees
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Healthcare · Biotechnology · 113 employees
ANL vs JANX FAQ
Which is bigger, Adlai Nortye Group or Janux Therapeutics?
Janux Therapeutics (JANX) is larger, with a market capitalization of $1.13B compared with $998.81M for Adlai Nortye Group (ANL).
Which stock has performed better over the past year, ANL or JANX?
ANL returned +796.53% over the past 12 months, compared with -23.55% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Janux Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.